LEADERSHIP: THE TERMEER FOUNDATION BOARD OF DIRECTORS


 

Belinda Termeer

Belinda Termeer


The Termeer Foundation Roles:
President, Co-Founder and Member of the Board of Directors

External Roles:
Head of the Termeer family office; member of the Board of Directors of PIC Therapeutics, the Board of Fellows and the Discovery Committee at Harvard Medical School, the President's Council at Massachusetts General Hospital, the Board of Directors of Celebrity Series of Boston, the leadership council of the Silent Spring Institute, and the Women in Science and Engineering Committee at the Museum of Science; Trustee Emerita of the Boston Ballet

Belinda brings unparalleled passion to The Termeer Foundation, as well as significant experience serving on boards of directors for both nonprofit and for-profit organizations, both within and beyond the life sciences industry. In 1998, together with her late husband, Henri Termeer, she started the Termeer family office and has since managed its assets. In 2011, she and Henri established the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital with the goal of developing a best in class center for personalized medicine, building on Henri’s work as Genzyme's CEO focused on rare diseases.


hasan 375

Alan Walts


The Termeer Foundation Roles:
Treasurer, Secretary, Mentor, Co-Founder and Member of the Board of Directors

External Roles:
Executive Chairman of PIC Therapeutics, Artax Biopharma, and Zikani Therapeutics; Board Observer at Aura Biosciences, Amylyx Pharmaceuticals and Arrakis Therapeutics; US-based Venture Partner with Advent Life Sciences; Advisory Board Member of the ALS Investment Fund

Alan brings more than three decades of experience in the business of biotechnology to The Termeer Foundation. He also worked alongside Henri Termeer for more than 20 years at Genzyme, and later served as Henri’s Business Advisor.

Alan first met Henri in 1983 at Genzyme and had the remarkable good fortune to learn from Henri for several decades thereafter. While demanding excellence, Henri provided regular advice, guidance, and mentoring as Alan moved through business development, business strategy, research and development, general management, and venture capital positions at Genzyme. Prior to leaving Genzyme in 2013, Alan managed Genzyme’s corporate venture fund, Genzyme Ventures (now Sanofi Ventures). After leaving Genzyme, Alan served as Henri’s Business Advisor, working closely with him on founding and investing in early stage companies.

Alan received a Ph.D. in chemistry from MIT in 1985, carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the executive Program for Management Development at Harvard Business School.


John Maraganore

John Maraganore


The Termeer Foundation Roles:
Mentor and Member of the Board of Directors

External Roles:
CEO and Director at Alnylam Pharmaceuticals, Chair of the Board for Agios Pharmaceuticals, co-chair of the Termeer Tribute Committee, and member of the Biotechnology Innovation Organization (BIO) Executive Committee.

John brings The Termeer Foundation extensive experience gained from building and managing the translation of RNAi from a Nobel Prize-winning discovery into an innovative, entirely new class of medicines, and in the process creating one of the biopharmaceutical industry’s largest and arguably most successful companies.

John has served as the CEO and a Director of Alnylam since 2002. Prior to Alnylam, John served as an officer and a member of the management team for Millennium Pharmaceuticals, and prior to that he held various positions at Biogen, where he invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, formerly HIRULOG™ and currently marketed by The Medicines Company. Prior to Biogen, John was a scientist at ZymoGenetics, Inc., and the Upjohn Company. John also formerly served as Chair of the Board of Directors for the Biotechnology Industry Organization (BIO). John received his MS and PhD in biochemistry and molecular biology at the University of Chicago.


Joan Reede, M.D.

Joan Reede, M.D.


The Termeer Foundation Roles:
Member of the Board of Directors

External Roles:
Dean for Diversity and Community Partnership at Harvard Medical School, President of the Biomedical Science Careers Program.

Joan brings to The Termeer Foundation a lifelong passion for and experience with mentoring and supporting diversity in the biosciences. She is Harvard Medical School’s first Dean for Diversity and Community Partnership, responsible for the development and management of a comprehensive program that provides leadership, guidance, and support to promote the increased recruitment, retention, and advancement of underrepresented minority faculty. She also serves in a number of other positions, including Faculty Director of Community Outreach at HMS, Professor at HMS and at Harvard’s Chan School of Public Health, and Assistant in Health Policy at Massachusetts General Hospital.

While at HMS, Joan created more than 20 diversity and leadership-focused programs, including founding the HMS Minority Faculty Development Program and the Biomedical Careers Program. Before joining Harvard, she served as the medical director of a Boston community health center and worked as a pediatrician in community and academic health centers, juvenile prisons, and public schools. She has held a number of advisory roles including serving on the Health and Human Services Advisory Committee on Minority Health and the Secretary’s Advisory Committee to the Director of NIH. Joan graduated from Brown University and Mount Sinai School of Medicine. She holds an MPH and an MS in Health Policy Management from Harvard T. H. Chan School of Public Health, and an MBA from Boston University.


Gail Maderis

Gail Maderis


The Termeer Foundation Roles:
Member of the Board of Directors

External Roles:
President and CEO of Antiva Biosciences, member of the Board of Directors at Valitor Inc., the Biotechnology Innovation Organization (BIO), and the California Life Sciences Institute

Gail has over 20 years of leadership in biopharmaceutical companies, including at Genzyme, where she worked closely with Henri Termeer. In addition to her role as President and CEO of Antiva, she serves on the boards of Valitor, the Biotechnology Innovation Organization (BIO), and the California Life Sciences Institute, and she is a Trustee of the University of California Berkeley Foundation.

Previously, Gail led BayBio, the industry organization representing and supporting Northern California’s life science community. She also previously served as President and CEO of Five Prime Therapeutics, Inc., and held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology (GZMO). Gail also practiced management and strategy consulting with Bain & Co. She received a BS in business from UC Berkeley and an MBA from Harvard Business School.


Adriana Termeer

Adriana Termeer


The Termeer Foundation Roles:
Observing member of the Board of Directors

External Roles:
Student

As Henri’s daughter, Adriana brings a passion for the Termeer legacy to the board at The Termeer Foundation. In addition to observing board proceedings and representing the foundation at events, Adriana is studying at Georgetown University.

 


The Termeer Foundation Advisory Board


Sun Altbach

Sun Altbach has more than 20 years of experience in life sciences. Most recently she served as President, Founding CEO and Board Member for PIC Therapeutics, an oncology company focused on modulation of RNA translation. Prior to that she held a number of senior roles across diverse theraputic areas, spanning public, private, large and early stage biopharmaceutical companies. Positions included Vice President of Program Management and Operations at Finch ( formerly Crestovo), Senior Director of Global Technical Development and Operations at OvaScience, Head of Research and Nonclinical Development Operations at Shire, and Program and Portfolio Management at Genzyme (now Sanofi Genzyme). It was at Genzyme that she experienced the impact of the "patients first" mantra and the importance of both mentorship and entrepreneurship that Henri Termeer championed. Altbach has been based in both the US and abroad over the course of her career and holds an MBA from MIT’s Sloan School of Management and an undergraduate degree from Smith College.

Daniel De Boer

Daniel is Founder and Chief Executive Officer of ProQR Therapeutics. After one of his children was diagnosed with a rare disease, he started ProQR to develop RNA therapies for rare diseases. Under Daniel’s leadership ProQR developed a platform that yielded a diversified pipeline of potential treatments for rare diseases, and raised approx $400M in funding, including an IPO on Nasdaq. Before founding ProQR, Daniel was founder and Chief Executive Officer of several technology companies. Daniel is also co-founder and strategic advisor to Amylon Therapeutics and Wings therapeutics, strategic advisor at Frame Therapeutics, Meatable and Algramo and a member of the board at the Termeer Foundation. In 2018 Daniel was named "Emerging Entrepreneur of the Year" by EY. In 2019 Daniel was selected for the Young Global Leader program at the World Economic Forum.

Daniel met Henri in late 2011, after stalking him for months to get a meeting. 6 months later they co-founded ProQR Therapeutics. Daniel had the privilege of working closely with Henri as a board member in the years after and benefit from his mentorship in building ProQR.

Eli De Los Pinos

Eli de los Pinos is the founding CEO of Aura, which she created from the ground up: She developed the company concept collaborating with Lasker award winner Dr. John Schiller at the National Cancer Institute and spearheaded fundraising efforts, raising a total of $140M in multiple rounds of financing. Prior to founding Aura, she worked in Eli Lilly & Co.’s oncology business unit, where she was part of the leadership team responsible for the market launch in Europe of Alimta, a drug for the treatment of lung cancer. Earlier in her career, Eli worked as a post-doctoral fellow at the Institute of Cancer Research in London. She previously completed fellowships at the Mount Sinai School of Medicine Institute of Molecular Medicine and at the Georgetown School of Medicine. Eli holds a Ph.D., magna cum laude, in Molecular Biology from the University of Barcelona and an MBA from IE Business School.

She is a member of the board of overseers at the Museum of Science, Boston. Eli has also been named to Boston Business Journal's “Top 40 under 40” list; as a Mass High Tech “Woman to Watch”; as a “Technology Pioneer” by the World Economic Forum; and as one of Goldman Sachs’ “100 Most Intriguing Entrepreneurs”.

Eli first met Henri in 2010 right after moving to Boston from Spain to start Aura. As a first time female CEO, Eli was privileged to have Henri’s mentorship in those early and challenging years guiding her to define the company’s strategy and Board of Directors, actively participating in her seed round of angel investors and in every financing round thereafter, introducing her to his closest business network and later becoming a Board member and key strategic advisor.

Geoff McDonough

Geoff McDonough is the President & Chief Executive Officer of Generation Bio. Geoff formerly served as president and chief executive officer of Swedish Orphan Biovitrum AB (Sobi) from 2011 – 2017. Prior to Sobi, he held a variety of senior roles at Genzyme Corporation, including president of Genzyme Europe and senior vice president and general manager of the global lysosomal storage disease business.

Geoff has a Bachelor of Science in biology and a Bachelor of Arts in philosophy from University of North Carolina at Chapel Hill, graduating summa cum laude in both. He obtained his doctor of medicine at Harvard Medical School and completed his residency training in internal medicine and pediatrics at Massachusetts General Hospital and Boston Children’s Hospital.

Trista Morrison

Trista Morrison has nearly 20 years of experience in healthcare public affairs, including strategic communications and patient advocacy. She currently serves as Chief Communications Officer for rare disease company Saniona. Previously, she founded the consulting firm PR with Purpose, LLC. Prior to that she served as Vice President of Communications and Patient Advocacy for rare disease company Sobi in North America, where she built both departments and supported milestones including FDA approvals, product launches, acquisitions, significant data disclosures, and growth from 50 to 300 employees. Prior to joining Sobi, Morrison managed corporate, product and employee communications for Ironwood Pharmaceuticals Inc. She previously worked as a reporter for BioWorld Today and held various positions at multiple biotech public relations agencies. Morrison currently serves on the Board of Directors for the Network of Tyrosinemia Advocates (NOTA).

termeer logo bottom